JERSEY CITY, N.J., Sept. 25, 2018 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the launch of its Clinical Trial Transparency Service (CTTS). This transparency and health literacy management solution enables clinical trial sponsors to engage with patients, healthcare professionals, researchers and the public via a dedicated clinical trial informational website. The company is debuting this service with three customers that are among the top 20 pharmaceutical companies in the world.
As the demand for accurate and understandable clinical trial transparency from regulatory and patient advocacy groups continues to grow, TrialScope's CTTS allows sponsors to position themselves as pioneers in trial data sharing, trial literacy, trial recruitment optimization, patient education and retention. In addition, under the new service, the sponsor's website is automatically updated with information submitted to Clinicaltrials.gov, eliminating redundant processes and associated costs, and improving reporting accuracy.
"Today, more than ever, patients are seeking clinical trial information on the web. This, coupled with calls for transparency, highlights a major need in the industry for a way to disseminate important, easy-to-understand information such as plain language summaries (PLS), or respond to data requests," said Jeff Kozloff, CEO of TrialScope. "We're excited to share our newest solution with the clinical trial community and look forward to helping sponsors deliver meaningful clinical trial data and clear communications to help patients find, share, enroll and stay engaged in studies."
CTTS leverages digital and mobile platforms, social media and patient engagement to deliver an unprecedented opportunity for clinical trial sponsors, participants and researchers to find each other with greater speed and precision. In addition, CTTS enables more meaningful engagement, which can help accelerate the process of clinical trial recruitment.
CTTS offers a variety of benefits to both patients and sponsors, including:
CTTS is available immediately to sponsors and is easily integrated with TrialScope's other offerings, or external systems. For quick deployment, sponsors can select from a number of best practice website design templates. Sponsors can also work directly with TrialScope to develop a custom layout and design.
For more information on TrialScope or its Clinical Trial Transparency Service, visit trialscope.com.
About TrialScope
TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that are designed to optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit trialscope.com.
SOURCE TrialScope
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.